A multicenter, randomized, open-label phase 3 study to investigate the efficacy and safety of aldoxorubicin compared to investigator's choice in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who either relapsed or were refractory to prior non-adjuvant chemotherapy

Trial Profile

A multicenter, randomized, open-label phase 3 study to investigate the efficacy and safety of aldoxorubicin compared to investigator's choice in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who either relapsed or were refractory to prior non-adjuvant chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Aldoxorubicin (Primary) ; Dacarbazine; Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide; Pazopanib
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 05 Jul 2017 This trial has been Discontinued in France and Germany.
    • 23 Jun 2017 This trial has been Discontinued in UK (End date: 2017-04-12).
    • 08 Jun 2017 According to a CytRx Corporation media release, data from this and another study Phase 2b (CTP700051416) will be used in NDA filing for aldoxorubicin in soft tissue sarcomas (STS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top